Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 46, 2022 - Issue 4
94
Views
1
CrossRef citations to date
0
Altmetric
Brief Report

Dominantly Inherited β-Thalassemia Caused by a Single Nucleotide Deletion in Exon 3 of the β-Globin Gene: Hb Xiangyang (HBB: c.393delT)

, , &
Pages 253-255 | Received 29 Dec 2021, Accepted 03 Feb 2022, Published online: 10 Jun 2022
 

Abstract

We report a de novo frameshift mutation in exon 3 of the β-globin gene that leads to a β-thalassemia (β-thal) intermedia (β-TI) phenotype in a 6-year-old Chinese boy. This novel mutation with deletion of the last nucleotide (–T) at codon 130 results in a β-globin chain that is extended to 156 amino acid residues. This study highlights the importance of considering dominantly inherited β-thal in the investigation of anemia, even in patients with ethnic backgrounds not usually associated with β-thal and hematologically normal parents.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Additional information

Funding

This study was supported by grants from the Provincial Department of Science and Technology Agency of Guangdong [2021A1515220088] and the Guangzhou Institute of Pediatrics/Guangzhou Women and Children’s Medical Center [IP-2019–004], Guangzhou, Guangdong Province, People’s Republic of China.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.